Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Sarcoma

2951 - Immune response, safety, and overall survival of NY-ESO-1+ soft tissue sarcoma patients treated with CMB305 therapy

Date

22 Oct 2018

Session

Poster Discussion session - Sarcoma

Topics

Clinical Research;  Immunotherapy;  Soft Tissue Sarcomas

Presenters

Sant Chawla

Citation

Annals of Oncology (2018) 29 (suppl_8): viii576-viii595. 10.1093/annonc/mdy299

Authors

S.P. Chawla1, S. Pollack2, M. Block3, M. Druta4, K. Do5, J.C. Morris6, J.W. Kim7, C. Bohac8, H. Lu9, S. Gnjatic10, R.L. Jones11, P. Hwu12, N. Somaiah13

Author affiliations

  • 1 Medical Oncology, Sarcoma Oncology Center, 90403 - Santa Monica/US
  • 2 Medical Oncology, Fred Hutchinson Cancer Research Center, Seattle/US
  • 3 Department Of Oncology, Mayo Clinic, 55905 - Rochester/US
  • 4 Medical Oncology, Moffitt Cancer Center, Tampa/US
  • 5 Medical Oncology, Dana Farber Cancer Institute, Boston/US
  • 6 Medical Oncology, University of Cincinnati, Cincinnati/US
  • 7 Medical Oncology, Yale University, New Haven/US
  • 8 Clinical Development, Immune Design, South San Francisco/US
  • 9 Science, Immune Design, Seattle/US
  • 10 Immunology, Mt Sinai, New York City/US
  • 11 Medical Oncology, Royal Marsden Hospital NHS Foundation Trust, SW3 6JJ - London/GB
  • 12 Medical Oncology, MD Anderson Cancer Center, 77030 - Houston/US
  • 13 Medical Oncology, MD Anderson Cancer Center, Houston/US
More

Resources

Abstract 2951

Background

CMB305 is an active immunotherapy regimen designed to generate and expand anti-NY-ESO-1 T and B cells. It consists of priming with a dendritic cell-targeting lentiviral vector encoding NY-ESO-1, and a boost with NY-ESO-1 recombinant protein plus TLR-4 agonist. This first-in-human study of CMB305 examined safety, immune response (IR), and efficacy in pts with NY-ESO-1 positive (+) solid tumors. At ASCO2017, median overall survival (OS) for soft tissue sarcoma (STS) was not reached (12 mos OS rate 83%).

Methods

Adults with previously treated NY-ESO-1+ solid tumors were enrolled in a 3 + 3 dose-escalation with an expansion phase 1b study. The CMB305 regimen included 4 intradermal injections of the prime, alternating with 3 intramuscular boost injections over 3 months, then bimonthly boost injections up to 1 yr. An updated STS survival analysis was performed.

Results

As of 06 April 2018, 25 pts with STS (15 synovial (SS), 8 myxoid/round cell liposarcoma (MRCL), 2 other) were evaluable for safety; 24 pts were evaluable for IR and efficacy. All pts received prior therapy for advanced disease, 67% > =2 prior chemo regimens. No dose limiting toxicities were observed. Most treatment related adverse events were Grade 1 or 2; one Grade 3 (prostatic pain); no grade 4 or 5 events. Best tumor response was stable disease in 8/15 (53%) SS pts and 6/8 (75%) MRCL pts with evidence of tumor growth arrest. The median progression free survival (PFS) was 3.9 mos (2.1, 7.5) for STS and 3.7 mos (2.1, 7.8) for SS. Median OS was 23.7 mos (15.5, NR) for STS and 29.2 mos (12.2, NR) for SS. Presence of anti-NY ESO 1 antibodies (Ab) at baseline (25.0% pts) was associated with longer survival. Anti-NY-ESO-1 specific T cells and Ab developed in 46% and 67% STS pts, respectively. Pts with baseline and induced anti-NY-ESO-1 IR (T-cells and/or antibodies) had a trend to improved clinical outcomes. T cell receptor sequencing indicated increased clonality and antigen spreading was observed.

Conclusions

CMB305 is well tolerated, broadly immunogenic, and impacts patient survival favorably when compared with approved agents for recurrent STS. These results support a randomized phase 3 trial evaluating CMB305 in the maintenance setting after 1st line therapy in SS patients.

Clinical trial identification

NCT02387125.

Legal entity responsible for the study

Immune Design Corp.

Funding

Immune Design Corp.

Editorial Acknowledgement

None

Disclosure

S.P. Chawla: Advisory board: Amgen, Immune Design, Novartis, PharmaMar, Janssen, Five Prime; Research funding: Amgen, Novartis, Immune Design, Five Prime, Roche, Karyopharm, BMS, Janssen, Blueprint Medicines, PharmaMar, CBA; Stock ownership: EOI, Cellestia, Uptick, Health Centerpoint, Biomedica. M. Druta: Consulting/advisory board: Eisai, Lilly. C. Bohac: Employee, stock ownership: Immune Design, Amgen. H. Lu: Employee, stock ownership: Immune Design. N. Somaiah: Advisory board: Immune Design. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.